对比增强超声在MRI未能明确表征的肝硬化患者小肝结节中的诊断效能
该研究为单中心前瞻性队列的事后分析,纳入75个筛查超声发现、MRI分类不确定(LI-RADS-2/3/4/M)的≤20 mm肝结节,评估加做CEUS(对比增强超声)后的诊断效能。CEUS将21.1%的结节升级为CEUS-LR5,诊断HCC的敏感度为37.5%(95%CI:22.73‒54.20%),特异度为100%(95%CI:88.78-100%)。作者认为CEUS是解决MRI不确定小结节问题的有价值工具,尤其使MRI LR3结节获益。
要点
- MRI不确定的≤20 mm肝硬化结节中,加做CEUS后21.1%被分类为CEUS-LR5。
- CEUS诊断HCC的敏感度为37.5%(95%CI:22.73‒54.20%),特异度为100%(95%CI:88.78-100%)。
- CEUS对MRI分类为LR3的结节获益尤其明显。
核心结论
- 在MRI表现不确定的肝硬化患者小肝结节(≤20 mm)中,加做CEUS诊断HCC具有高特异度(100%,95%CI:88.78-100%)和较低敏感度(37.5%,95%CI:22.73‒54.20%),尤其使MRI分类为LR3的结节获益。
研究设计与样本
- 单中心前瞻性队列研究的事后分析,纳入2006年1月至2017年2月间筛查超声发现新发≤20 mm肝结节、且在MRI分类不确定(LI-RADS-2、LI-RADS-3、LI-RADS-4或LI-RADS-M)后接受CEUS的高危患者(Child A或B级,无HCC病史),共75个结节;以活检或随访的最终诊断作为参考标准,比较单独使用LI-RADS v.2018与结合后续CEUS-LR v.2017对结节的分类效能。
诊断标准与关键数值
- CEUS对HCC的诊断敏感度为37.5%(95%CI:22.73‒54.20%),特异度为100%(95%CI:88.78-100%);75个结节中CEUS升级45个(63.4%),其中MRI分类为LR3或LR4的13个结节被分类为CEUS-LR5;合计15个(21.1%)MRI不确定结节被分类为CEUS-LR5。
临床应用与阅片要点
- 作者认为CEUS是解决肝硬化患者小肝结节MRI不确定问题的有价值工具,尤其对MRI分类为LR3的结节有益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: In patients at risk of hepatocellular carcinoma (HCC), new focal liver lesions identified at ultrasound screening require further characterization by CT or MRI. If these techniques cannot conclusively characterize a lesion, a biopsy or an alternative imaging modality such as contrast-enhanced ultrasound (CEUS) is considered. We aimed to determine the diagnostic yield of CEUS in a sequential noninvasive diagnostic strategy for solitary nodules ≤ 20 mm detected in cirrhotic patients during US surveillance characterized as inconclusive on MRI.
METHODS: Post hoc analysis of a single-center prospective cohort of high-risk patients (Child A or B) with no prior history of HCC and new liver nodules (≤ 20 mm) detected on screening US who underwent CEUS after inconclusive MRI (LI-RADS-2, LI-RADS-3, LI-RADS-4, or LI-RADS-M) between January 2006 and February 2017. We compared the characterization of nodules by LI-RADS v.2018 alone vs characterization after considering subsequent CEUS-LR v.2017 against the final diagnosis by biopsy or follow-up.
RESULTS: Of the 75 nodules included, CEUS upgraded 45 (63.4%); of these, 13 nodules classified as LR3 or LR4 at MRI were classified as CEUS-LR5. Altogether, 15 (21.1%) nodules inconclusive on MRI were classified as CEUS-LR5. CEUS yielded 37.5% (95% CI: 22.73‒54.20%) sensitivity and 100% specificity (95% CI: 88.78-100%) for HCC.
CONCLUSION: Adding CEUS to the workup of liver nodules with inconclusive MRI findings demonstrated high specificity for HCC, particularly benefiting nodules categorized as LR3 at MRI.
KEY POINTS: Question MRI's limited sensitivity in diagnosing small HCCs in cirrhotic patients results in inconclusive classification of a high proportion of screening-detected lesions. Findings Adding CEUS to the work-up for inconclusive liver nodules at MRI yielded 100% specificity (95% CI: 88.78-100%) and 37.5% (95% CI: 22.73-54.20%) sensitivity for the HCC diagnosis. Clinical relevance CEUS is a valuable problem-solving tool in the work-up of small liver nodules with inconclusive MRI findings in cirrhotic patients.
引用
- Saborido B, Darnell A, Forner A, et al. Diagnostic performance of contrast-enhanced US in small liver nodules not conclusively characterized after MRI in cirrhotic patients. Eur Radiol. 2025. PMID: 40055232. doi:10.1007/s00330-025-11495-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。